Clinical Trials · NCT07859176
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery
- Phase
- Phase 4
- Recruitment status
- Not Yet Recruiting
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Enrollment
- 100
- Start date
- Oct 2026
- Locations
- 1 site, Egypt
- Primary endpoint
- Percentage change in body weight